Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333758 | 0.80 | — | — | |
| SCHEMBL18032669 | 0.79 | — | — | |
| SCHEMBL18433148 | 0.72 | — | — | |
| SCHEMBL9486647 | 0.70 | ALDH1A1 (0.30) | — | |
| SCHEMBL18285261 | 0.69 | — | — | |
| SCHEMBL8660608 | 0.64 | — | — | |
| SCHEMBL14853510 | 0.64 | — | — | |
| SCHEMBL28890214 | 0.58 | — | — | |
| SCHEMBL27382541 | 0.54 | ITGB2 (0.53) | ITGB2ICAM1ITGAL | |
| SCHEMBL3289443 | 0.54 | ITGB2 (0.44) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091012-B1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CENTREXION THERAPEUTICS CORP (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2922841-B1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2917206-B1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2016179460-A1 | TRICYCLIC SULFONES AS RORϒ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| EP-2175885-B1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES INC (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015103509-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103508-A1 | CARBOCYCLIC SULFONE RORγ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103510-A1 | HETEROCYCLIC SULFONE AS ROR-GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103507-A1 | CYCLOHEXYL SULFONE RORϒ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-2067775-B1 | A N-Acylsphingosine glucosyltransferase inhibitor | GENZYME CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-1409467-B1 | A N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITOR | GENZYME CORP (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011007722-A1 | 3-SUBSTITUTED-2-FURANCARBOXYLIC ACID HYDRAZIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2011-01-20 | — | — | WO | disclosed |
| EP-2266968-A2 | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010131669-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2010-11-18 | — | — | WO | disclosed |
| US-20100167178-A1 | Oxime sulfonates and the use thereof as latent acids | YAMATO HITOSHI | 2010-07-01 | — | — | US | disclosed |
| US-20100167178-A1 | Oxime sulfonates and the use thereof as latent acids | YAMATO HITOSHI | 2010-07-01 | — | — | US | disclosed |
| EP-2067775-A1 | Synthesis of UDP-glucose: N-Acylsphingosine glucosyltransferase inhibitors | GENZYME CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7199145-B2 | Derivatives of hydantoins, thiohydantoins, pyrimidinediones and thioxopyrimidinones, their preparation processes and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D' 'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | ITGB2 4762/4885ICAM1 3572/4885ITGAL 4771/4885 |
| US-20100167178-A1 | Oxime sulfonates and the use thereof as latent acids | HAO2, SULT2A1, ARSA | ITGB2 598/4885ICAM1 1124/4885ITGAL 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.